ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
Two Onc Docs
00:00
Overview of the LORA Trial and Its Impact on Treatment Strategies
This chapter delves into the LORA trial's findings, emphasizing the superiority of osimertinib over dervalumab for patients with unresectable stage III EGFR-mutant non-small cell lung cancer. It discusses key aspects such as progression risk reduction, trial crossover benefits, and recent updates from the ASCO plenary session.
Transcript
Play full episode
